2021

October 14, 2021
Tizona Initiates Phase 1b Expansion Study of TTX-080 in Advanced Refractory or Resistant Malignancies

2020

September 15, 2020
Tizona Appoints Christine O’Brien as Chief Executive Officer

July 21, 2020
Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million

June 25, 2020
Tizona Initiates Clinical Development of TTX-080 in Advanced Cancers 

February 19, 2020
Tizona to Present at The Cowen and Company 40th Annual Healthcare Conference

2019

November 07, 2019
Tizona Announces Publication in Cancer Discovery Highlighting the Important Role of CD39 and Extracellular ATP in Inflammasome-driven Anti-Tumor Immunity

July 11, 2019
Tizona Appoints Joyson Karakunnel, MD, MSc, FACP as Senior Vice President and Chief Medical Officer

May, 15, 2019
Tizona Elects Daniel K. Spiegelman to Its Board of Directors

March 27, 2019
Tizona Announces Initiation of Phase 1/1b Study with Novel Cancer Immunotherapy TTX-030 and First Public Presentation of Pre-Clinical Data with TTX-030 at AACR 2019

January 3, 2019
AbbVie and Tizona Therapeutics Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39

January 3, 2019
Tizona Therapeutics Appoints Scott Clarke as Chief Executive Officer and Provides Update on Regulatory Milestone for its First-in-Class CD39 program in Cancer

2018

April 18, 2018
ProBioGen signs Second Contract Development Agreement with Tizona Therapeutics for Immuno-Oncology Antibody Project

2016

August 30, 2016
Tizona Therapeutics, Inc. Appoints George Golumbeski, Ph.D., to its Board of Directors

March 8, 2016
Tizona Therapeutics, Inc., Completes $43 Million Series B Financing

2015

October 1, 2015
ProBioGen Inks Another Commercial GlymaxX® License and Contract Manufacturing Service Agreement on Immuno-Oncology Antibody

May 21, 2015
MPM Capital announces the appointment of former President of Onyx Pharmaceuticals Pablo J. Cagnoni, M.D. as Managing Director (MD)